BiotechTV - News

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

He discusses the theme of his annual letter that was published today, "Choosing Science," and why it is important that our country continues to invest in basic research. Plus, his take on the M&A environment in biotech.

He discusses Biohaven, Xenon, Biogen, and Sarepta.

Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.